The Technical Analyst
DBV Technologies S.A. [DBVT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
DBV Technologies S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.74% $0.665
America/New_York / 24 apr 2024 @ 14:17
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127.96 mill |
| EPS: | -0.380 |
| P/E: | -1.750 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 192.42 mill |
| Avg Daily Volume: | 0.0553 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.750 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.750 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.603 - 0.727 ( +/- 9.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
| 2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
| 2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
| 2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
| 2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
| INSIDER POWER |
|---|
| 99.86 |
| Last 57 transactions |
| Buy: 29 162 445 | Sell: 1 080 406 |
Forecast:
15:56 - $0.676
Live Trading Signals (every 1 min)
Forecast
1: 14:26 - $0.690
Forecast 2: 15:16 - $0.678
Forecast 3: 15:56 - $0.676
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.665 (-5.74% ) |
| Volume | 0.0016 mill |
| Avg. Vol. | 0.0553 mill |
| % of Avg. Vol | 2.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DBVT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Latest Press Releases
2024-03-08 09:33:00 - Press Release
Dbv Technologies Announces Filing Of 2023 Annual Report On Form 10-k And Universal Registration Document
Montrouge, france, march 8, 2024 dbv technologies announces filing of 2023 annual report on form 10-k and universal registration document dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “company”), today announced the filing, for the year ended december 31, 2023, of its annual report on form 10-k with the u.s. securities and exchange commission (“sec”) and its universal registration document (“urd”) with the french market authority, “autoritÉ des marchÉs financiers” (“amf”)...
2024-03-07 16:30:00 - Press Release
Dbv Technologies Reports Full Year 2023 Financial Results And Business Update
Montrouge, france, march 7, 2024 dbv technologies reports full year 2023 financial results and business update advanced viaskin™ peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) strengthened executive leadership team in preparation for bla submission reported cash and cash equivalents of $141 million dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. the audit procedures have been substantially completed by the company's statutory auditors and financials – prepared under both us gaap and ifrs for the purpose of form 10-k and universal registration document respectively – were approved by the board of directors on march 7, 2024.
2024-03-04 16:30:00 - Press Release
Dbv Technologies To Report Full Year 2023 Financial Results And Business Update On March 7, 2024
Montrouge, france, march 4, 2024 dbv technologies to report full year 2023 financial results and business update on march 7, 2024 dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the company will host a conference call and live audio webcast on thursday, march 7th, at 5:00 p.m. et to review full year 2023 financial results and provide a business update.
2024-02-20 16:30:00 - Press Release
Dbv Technologies To Participate In Upcoming Aaaai 2024 Congress
Montrouge, france, february 20 2024 dbv technologies to participate in upcoming aaaai 2024 congress dbv technologies (euronext: dbv – isin: fr0010417345 –nasdaq: dbvt), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the american academy of allergy, asthma, and immunology (aaaai) annual meeting, february 23-26 in washington, d.c. a poster presentation by david fleischer, m.d.
2024-01-16 16:30:00 - Press Release
Half-year Report On The Dbv Technologies Liquidity Contract With Oddo Bhf
Amf regulated information montrouge, france, january 16, 2024 half-year report on the dbv technologies liquidity contract with oddo bhf dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company, today issued the half-year report on its liquidity contract with natixis oddo bhf. under the liquidity contract between dbv technologies and natixis oddo bhf, the following assets appeared on the liquidity account as of december 31, 2023: 222,988 dbv technologies shares, € 150,264.71.
Latest News
2024-03-04 16:30:00 - GlobeNewsWire
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.
2023-12-01 10:47:45 - Benzinga
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-11-27 11:19:38 - Zacks Investment Research
Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
2023-11-02 16:30:00 - GlobeNewsWire
DBV Technologies to Present New Data at ACAAI 2023
Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
2023-10-31 21:57:09 - Seeking Alpha
DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Operator Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call.
2023-10-27 16:30:00 - GlobeNewsWire
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.
2023-09-05 16:30:00 - GlobeNewsWire
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY.
2023-07-25 16:30:00 - GlobeNewsWire
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.
2023-06-06 17:00:00 - GlobeNewsWire
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, June 06, 2023 DB V Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference taking place on June 12th – 15th in Dana Point, CA. Daniel Tassé, Chief Executive Officer, will engage in a Fireside Chat session on Wednesday, June 14th at 10:00am PST (1:00pm EST), as well as one-on-one investor meetings throughout the day.
2023-05-11 15:31:03 - The Motley Fool
Why Shares of DBV Technologies Jumped Thursday
The company's peanut allergy treatment patch could have a wide impact. DBV Technologies currently has no marketed products.